Kevin Pak | Medicine | Best Researcher Award

Dr. Kevin Pak | Medicine | Best Researcher Award

Transplant Hepatology Fellow | UCLA | United States

Dr. Kevin C. Pak, M.D., is a distinguished transplant hepatologist affiliated with the Pflieger Liver Institute at the David Geffen School of Medicine at UCLA. With a strong background in internal medicine, gastroenterology, and hepatology, Dr. Pak has dedicated his career to advancing liver disease treatment and transplantation. His contributions to academic research and clinical practice have earned him recognition in the medical community.

Profile👤

Google Scholar

Scopus

Strengths for the Awards✨

Exceptional Research Contributions: Dr. Pak has an extensive portfolio of peer-reviewed publications in prestigious journals, covering a range of topics in gastroenterology, hepatology, and military medicine. His research on hepatitis B, hepatocellular carcinoma, liver transplantation, and inflammatory bowel disease is particularly noteworthy.

Clinical and Academic Leadership: As an Assistant Professor at USUHS and a former Chief Fellow in a gastroenterology fellowship, Dr. Pak has demonstrated strong mentorship and leadership in academic medicine. His contributions to teaching and training future physicians further emphasize his dedication to research and education.

Recognized Excellence: Multiple honors and awards, including the AASLD Emerging Liver Scholar Award (2019) and Resident Researcher of the Year, highlight his significant impact in the field. His invited presentations and poster sessions at national and international conferences further validate his research reputation.

Interdisciplinary and Military Medicine Contributions: His unique background in military medicine and research contributions in military healthcare settings (e.g., inflammatory bowel disease in active-duty personnel) provide a broader impact beyond civilian medicine.

Education 🎓

Dr. Pak began his academic journey at the United States Military Academy (USMA) in West Point, New York, earning a B.S. in Life Sciences. He then pursued his medical degree at the F. Edward Hébert School of Medicine at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland. His postgraduate training includes an Internal Medicine Residency at Walter Reed National Military Medical Center, followed by a Gastroenterology & Hepatology Fellowship at Naval Medical Center San Diego. He further specialized in Transplant Hepatology through a fellowship at the Pflieger Liver Institute at UCLA.

Experience 💼

Dr. Pak has held several academic positions, including Assistant Professor of Medicine and Teaching Fellow at USUHS. He is actively involved in medical education, mentoring students and residents. His clinical expertise spans hepatology, transplant medicine, and gastroenterology, making him a key contributor to the field. Additionally, Dr. Pak has served in the military, where he provided medical services in critical care settings.

Research Interests On Medicine🔬

Dr. Pak’s research focuses on liver disease, hepatocellular carcinoma, chronic hepatitis B, and liver transplantation. He is particularly interested in optimizing treatment strategies for liver disease and investigating emerging therapies. His work contributes to advancements in hepatology, improving patient outcomes and clinical practices.

Awards 🏆

Dr. Pak has received numerous accolades throughout his career. He was honored with the Resident Researcher of the Year Award and the AASLD Emerging Liver Scholar Award. His excellence in teaching earned him the James J. Leonard Award for Excellence in Teaching. In his military service, he received commendations such as the Navy/Marine Corps Commendation Medal and the Joint Service Commendation Medal.

Publications 📚

Dr. Pak has authored multiple peer-reviewed publications in prestigious journals. His notable works include:

  • Systematic review of safety of selective androgen receptor modulators in healthy adults: implications for recreational users

    • Authors: JD Vignali, KC Pak, HR Beverley, JP DeLuca, JW Downs, AT Kress, …
    • Publication Year: 2023
    • Citations: 38
  • Wilson’s disease and iron overload: pathophysiology and therapeutic implications

    • Authors: K Pak, S Ordway, B Sadowski, M Canevari, D Torres
    • Publication Year: 2021
    • Citations: 23
  • Helicobacter pylori Treatment Regimen Selection and Eradication Rates Across Department of Defense Patients for Fiscal Years 2016-2018

    • Authors: ZC Junga, A Mertz, K Pak, M Singla
    • Publication Year: 2023
    • Citations: 9
  • The Patterns and Associated Cost of Serologic Testing for Helicobacter pylori in the U.S. Military Health System

    • Authors: K Pak, Z Junga, A Mertz, M Singla
    • Publication Year: 2020
    • Citations: 6
  • State of the art: Test all for anti-hepatitis D virus and reflex to hepatitis D virus RNA polymerase chain reaction quantification

    • Authors: E Umukoro, JJ Alukal, K Pak, J Gutierrez
    • Publication Year: 2023
    • Citations: 5
  • Occult HBV infection: a case series at a military treatment facility

    • Authors: K Pak, S Ordway, D Torres
    • Publication Year: 2020
    • Citations: 4
  • An acute presentation of chronic gastric volvulus

    • Authors: K Pak, Z Junga, P Young
    • Publication Year: 2020
    • Citations: 4
  • Decades of cough: Delayed recognition of atypical cystic fibrosis in an adult patient

    • Authors: A Chandel, K Pak, S Dooley, K Salazar
    • Publication Year: 2020
    • Citations: 3
  • A small blemish: isotretinoin-induced microscopic colitis

    • Authors: LR Dukate, K Pak, W O’Connell, Z Junga
    • Publication Year: 2022
    • Citations: 2
  • A Case of Whipple’s Disease With Concomitant Esophageal Candidiasis

    • Authors: R Choi, A Pazevic, K Pak, M Skaret, A Bachmann, R Wilkerson
    • Publication Year: 2024
    • Citations: 1

Conclusion 🔍

Dr. Kevin C. Pak, M.D., is a dedicated physician, educator, and researcher in hepatology and gastroenterology. His commitment to advancing liver disease treatment, coupled with his academic and clinical expertise, makes him a key figure in the field. Through his research, mentorship, and clinical practice, Dr. Pak continues to contribute significantly to medical science and patient care.

Anquan Shang | Medicine | Best Researcher Award

Prof. Anquan Shang | Medicine | Best Researcher Award

The Second People’s Hospital of Lianyungang | China

Prof. Anquan Shang is a distinguished Associate Chief Laboratory Technician and Clinical Laboratory Physician with an H-index of 26. At the age of 39, he has made significant contributions to the field of clinical laboratory diagnostics. As a master’s supervisor, he plays a crucial role in mentoring future medical professionals. He is currently affiliated with Shanghai Jiao Tong University and has extensive experience in tumor marker research and clinical diagnostics.

Profile👤

ORCID

Google Scholar

Scopus

Strengths for the Awards✨

  • Strong Research Productivity 

    • H-index of 26, indicating high citation impact.
    • Over 70 SCI and core journal publications as first or corresponding author.
    • Multiple high-impact factor papers in oncology, microbiology, and immunology.
  • Impressive Funding & Grants 

    • Secured multiple national and provincial-level research grants.
    • Led and participated in 13+ major projects in oncology, infection, and precision diagnostics.
  • Leadership & Recognition 

    • Head of key clinical departments and training programs in prestigious hospitals.
    • Recognized in Shanghai and Jiangsu talent programs, highlighting academic excellence.
  • Significant Innovations & Impact 

    • Contributions to liquid biopsy, tumor biomarkers, and infection diagnostics.
    • 5+ patents, demonstrating translational research impact.
  • Professional Network & Influence 

    • Active in national and international research communities.
    • Reviewer and editor for multiple scientific journals.

🎓 Education

His academic journey began with a specialization in medical laboratory technology at Xiangfan Vocational and Technical College (2005-2008). He then pursued a bachelor’s degree in medical laboratory science at Jiangsu University (2011-2014), followed by a master’s degree in clinical laboratory diagnostics at Ningxia Medical University (2014-2017). He furthered his expertise with a Ph.D. in clinical laboratory diagnostics from Tongji University (2017-2020), establishing a strong foundation for his research career.

🏥 Experience

Currently, he is a postdoctoral researcher in clinical laboratory diagnostics at Ruijin Hospital, affiliated with Shanghai Jiao Tong University (2025-present), focusing on tumor biomarker research. Since 2023, he has led the Clinical Laboratory Medicine Department at Lianyungang Second People’s Hospital, a key clinical specialty in Jiangsu Province. Previously, he completed another postdoctoral fellowship at Tongji University (2020-2022), researching tumor microenvironment and biomarkers. His clinical experience spans roles as a laboratory technician at various hospitals between 2008 and 2014, steadily advancing to leadership positions.

🔬 Research Interests On Medicine

His research focuses on:

1️⃣ Tumor immunology 🧬

2️⃣ Infection microecology and immune microenvironment remodeling 🦠

3️⃣ Precision molecular diagnostics for chronic diseases 🏥

4️⃣ Liquid biopsy techniques for early disease detection 💉

🏆 Awards

He has received numerous prestigious awards, including the Yancheng City Natural Science Achievement Award (3 times), the Yancheng Medical New Technology Introduction Award (5 times), and the Huaihai Science and Technology Progress Award (2nd Prize, twice). From 2019-2022, he was consecutively recognized as an Outstanding Young Scientific Researcher by the Shanghai Medical Association Laboratory Medicine Branch.

📚 Publications

  • Title: Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p-TGF-β1 axis
    Authors: A Shang, C Gu, W Wang, X Wang, J Sun, B Zeng, C Chen, W Chang, …
    Publication Year: 2020
    Citations: 372

  • Title: Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils
    Authors: A Shang, W Wang, C Gu, C Chen, B Zeng, Y Yang, P Ji, J Sun, J Wu, …
    Publication Year: 2019
    Citations: 147

  • Title: Exosomal KRAS mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression
    Authors: A Shang, C Gu, C Zhou, Y Yang, C Chen, B Zeng, J Wu, W Lu, W Wang, …
    Publication Year: 2020
    Citations: 100

  • Title: Tumor microenvironment: lactic acid promotes tumor development
    Authors: Y Gao, H Zhou, G Liu, J Wu, Y Yuan, A Shang
    Publication Year: 2022
    Citations: 80

  • Title: Exosomal miR-183-5p promotes angiogenesis in colorectal cancer by regulation of FOXO1
    Authors: A Shang, X Wang, C Gu, W Liu, J Sun, B Zeng, C Chen, P Ji, J Wu, …
    Publication Year: 2020
    Citations: 77

  • Title: Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer
    Authors: AQ Shang, J Wu, F Bi, YJ Zhang, LR Xu, LL Li, FF Chen, WW Wang, …
    Publication Year: 2017
    Citations: 77

  • Title: Knockdown of long noncoding RNA PVT1 suppresses cell proliferation and invasion of colorectal cancer via upregulation of microRNA-214-3p
    Authors: AQ Shang, WW Wang, YB Yang, CZ Gu, P Ji, C Chen, BJ Zeng, JL Wu, …
    Publication Year: 2019
    Citations: 70

  • Title: IGF2BP2 promotes the progression of colorectal cancer through a YAP‐dependent mechanism
    Authors: J Cui, J Tian, W Wang, T He, X Li, C Gu, L Wang, J Wu, A Shang
    Publication Year: 2021
    Citations: 62

  • Title: miR‐381‐3p restrains cervical cancer progression by downregulating FGF7
    Authors: A Shang, C Zhou, G Bian, W Chen, W Lu, W Wang, D Li
    Publication Year: 2019
    Citations: 62

  • Title: Vaginal microecological characteristics of women in different physiological and pathological period
    Authors: L Shen, W Zhang, Y Yuan, W Zhu, A Shang
    Publication Year: 2022
    Citations: 59

🔚 Conclusion

With a strong academic background, leadership in clinical laboratory medicine, and groundbreaking research in tumor immunology and molecular diagnostics, he continues to make significant contributions to medical science. His extensive experience, prestigious awards, and influential publications highlight his dedication to advancing clinical diagnostics and improving patient outcomes.

Qianghua Lv | Medicine | Best Researcher Award

Prof. Dr. Qianghua Lv | Medicine | Best Researcher Award

Shandong Academy of Agricultural Sciences | China

Dr. Qianghua LV is an Associate Researcher at the Institute of Animal Science and Veterinary Medicine (IASVM), Shandong Academy of Agricultural Sciences (SAAS). He earned his Ph.D. in Veterinary Pharmacology under the mentorship of Prof. DENG Xuming at Jilin University in 2020. His research focuses on developing novel therapeutic strategies targeting bacterial virulence factors, including bacterial hemolysin, Type III Secretion System (T3SS), and Type IV Pili (TFP). His work contributes significantly to understanding anti-infective mechanisms and advancing new drug development against bacterial infections.

Profile👤

ORCID

Strengths for the Awards✨

  • High-Impact Research Focus – Dr. LV Qianghua’s work on anti-infection mechanisms and natural compound-based drug development aligns with global health priorities, particularly in combating superbacterial infections. His research on bacterial virulence factors like hemolysin, T3SS, and TFP contributes to the development of novel antimicrobial strategies.

  • Quality Publications in Reputable Journals – He has multiple first-author and co-first-author publications in high-impact journals, such as Journal of Cellular and Molecular Medicine and Applied Microbiology and Biotechnology. These papers focus on novel antibacterial mechanisms and natural product inhibitors, demonstrating both innovation and scientific rigor.

  • Translational Impact – His research not only advances basic microbiology but also holds significant translational potential in developing new antibacterial therapies, an area of urgent medical need due to rising antibiotic resistance.

  • Collaborative and Multi-Disciplinary Approach – His collaborations with researchers across multiple disciplines (pharmacology, microbiology, and veterinary medicine) enhance the applicability of his findings beyond veterinary science, benefiting both animal and human health.

  • Contribution to Veterinary Medicine – As an Associate Researcher at the IASVM, SAAS, Dr. LV contributes significantly to veterinary pharmacology, a field essential for both agricultural and public health. His work has implications for livestock disease management and food safety, making it highly relevant for both academia and industry.

🎓 Education

  • Ph.D. in Veterinary Pharmacology, Jilin University, 2020
    • Advisor: Prof. DENG Xuming
    • Research Focus: Anti-infection mechanisms of natural compounds targeting bacterial virulence factors

💼 Experience

  • Associate Researcher, IASVM, SAAS (2020–Present)
    • Conducting research on antibacterial strategies targeting virulence factors
    • Screening natural compounds for inhibitory effects on bacterial infections
    • Developing new therapeutic agents against superbacterial infections

🔬 Research Interests On Medicine

  • 🦠 Discovery and screening of novel targets and lead compounds against superb acterial infections
  • 💊 Synergistic antibacterial effects and mechanisms of natural compounds and antimicrobial agents

📚 Selected Publications

  • Title: Inhibition of the type III secretion system by syringaldehyde protects mice from Salmonella enterica serovar Typhimurium
    Authors: Lv Q(#), Chu X(#), Yao X, Ma K, Zhang Y*, Deng X*
    Publication Year: 2019
    Journal: Journal of Cellular and Molecular Medicine

  • Title: Identification of the natural product paeonol derived from peony bark as an inhibitor of the Salmonella enterica serovar Typhimurium type III secretion system
    Authors: Lv Q(#), Li S(#), Wei H, Wen Z, Wang Y, Tang T, Wang J, Xia L*, Deng X*
    Publication Year: 2020
    Journal: Applied Microbiology and Biotechnology

  • Title: Phloretin potentiates polymyxin E activity against Gram-negative bacteria
    Authors: Du R(#), Lv Q(#), Hu W, Hou X, Zhou Y, Deng X, Sun L, Li L, Deng Y, Wang J
    Publication Year: 2021
    Journal: Life Sciences

  • Title: Commercialized artemisinin derivatives combined with colistin protect against critical Gram-negative bacterial infection
    Authors: Zhou Y, Liu B, Chu X, Su J, Xu L, Li L, Deng X, Li D*, Lv Q*, Wang J*
    Publication Year: 2022
    Journal: Communications Biology

  • Title: Isoflavone glucoside genistin, an inhibitor targeting Sortase A and Listeriolysin O, attenuates the virulence of Listeria monocytogenes in vivo and in vitro
    Authors: Liu M(#), Lv Q(#), Xu J, Liu B, Zhou Y, Zhang S, Shen X, Wang L
    Publication Year: 2023
    Journal: Biochemical Pharmacology

🔚 Conclusion

Dr. LV Qianghua has dedicated his research to developing innovative antibacterial strategies, focusing on targeting bacterial virulence factors. His contributions in natural compound screening and new drug development have advanced the fight against superbacterial infections. With numerous impactful publications and ongoing research, he continues to make significant strides in veterinary medicine and pharmacology.

Guoli Li | Medicine | Best Researcher Award

Dr. Guoli Li | Medicine | Best Researcher Award

Researcher | Hunan Provincial People’s Hospital (The First-Affiliated Hospital of Hunan Normal University) | China

Dr. Guoli Li, Ph.D., is an Assistant Professor at Hunan Provincial People’s Hospital and the First Affiliated Hospital of Hunan Normal University, located in Changsha, China. With expertise in Molecular Medicine, Cancer Research, and Nephrology, Dr. Li has contributed extensively to the scientific community, focusing on cutting-edge advancements in medical research.

Profile

Google Scholar

Strengths for the Awards

  • Extensive Research Background:
    Dr. Guoli Li has a strong academic and research foundation in molecular medicine, cancer research, and nephrology, with significant experience at reputable institutions like the University of Texas MD Anderson Cancer Center and Hunan Normal University.
  • Diverse Publication Record:
    Dr. Li has authored numerous high-impact publications in peer-reviewed journals such as Frontiers in Oncology, Genes and Diseases, and BMC Nephrology. These papers cover critical topics like cancer biomarkers, glomerulopathy, and ferroptosis in cancer, demonstrating expertise in innovative and clinically relevant research.
  • Bibliometric Contributions:
    Contributions to bibliometric studies (e.g., research on ferroptosis and mitophagy) highlight Dr. Li’s ability to analyze global research trends, adding to their scholarly influence.

Education 🎓

  • Ph.D. in Biochemistry and Molecular Biology (2013–2017)
    Central South University, Changsha, Hunan, China
  • B.S. in Biotechnology (2008–2012)
    Changchun University of Technology, Changchun, Jilin, China

Experience 💼

  • Research Scientist (09/2020–Present)
    Hunan Provincial People’s Hospital, Hunan Normal University, Changsha, Hunan, China
  • Postdoctoral Fellow (09/2018–08/2020)
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • Instructor (06/2018–06/2020)
    Guangzhou Medical University, Guangzhou, Guangdong, China
  • Technician (08/2012–08/2013)
    Sansure Biotech Inc., Changsha, Hunan, China

Research Interests On Molecular Medicine🔬

Dr. Li’s research spans:

  • Molecular mechanisms in cancer biology 🧬
  • Nephrology, focusing on lupus nephritis and glomerulopathy 🩺
  • Biomarker identification and therapeutic development 🚑

Awards 🏆

  • 2018: Outstanding Graduate
  • 2016-2017: Excellent Graduate Student
  • 2009-2010: Excellent Student and Excellent Student Leader

Publications 📚

  • Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing
    Authors: G Li, X Guo, L Tang, M Chen, X Luo, L Peng, X Xu, S Wang, Z Xiao, W Yi, …
    Year: 2017
    Citations: 43
  • Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients
    Authors: G Li, X Guo, M Chen, L Tang, H Jiang, JX Day, Y Xie, L Peng, X Xu, J Li, …
    Year: 2018
    Citations: 39
  • What’s the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients
    Authors: W Wang, H Liu, G Li
    Year: 2022
    Citations: 26
  • Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients
    Authors: J Heng, X Guo, W Wu, Y Wang, G Li, M Chen, L Peng, S Wang, L Dai, …
    Year: 2017
    Citations: 20
  • The research landscape of ferroptosis in cancer: a bibliometric analysis
    Authors: G Li, Y Liang, H Yang, W Zhang, T Xie
    Year: 2022
    Citations: 17
  • Mutation screening of 10 cancer susceptibility genes in unselected breast cancer patients
    Authors: Y Xie, G Li, M Chen, X Guo, L Tang, X Luo, S Wang, W Yi, L Dai, J Wang
    Year: 2018
    Citations: 16
  • Hyperuricemia is an independent risk factor for renal pathological damage and poor prognosis in lupus nephritis patients
    Authors: T Xie, M Chen, X Tang, H Yin, X Wang, G Li, J Li, X Zuo, W Zhang
    Year: 2016
    Citations: 16
  • Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients
    Authors: H Deng, M Chen, X Guo, J Heng, X Xu, L Peng, H Jiang, G Li, JX Day, J Li, …
    Year: 2019
    Citations: 11
  • Bibliometric insights of global research landscape in mitophagy
    Authors: G Li, W Yin, Y Yang, H Yang, Y Chen, Y Liang, W Zhang, T Xie
    Year: 2022
    Citations: 10
  • LINC00467 is upregulated by DNA copy number amplification and hypomethylation and shows ceRNA potential in lung adenocarcinoma
    Authors: W Wang, H Bo, Y Liang, G Li
    Year: 2022
    Citations: 9

Conclusion 📝

Dr. Guoli Li is a passionate scientist and educator committed to advancing medical research and improving clinical outcomes. With numerous prestigious publications, awards, and invitations as a reviewer for reputed journals, Dr. Li continues to contribute profoundly to the global research community. 🌐